AZD8797

小分子

(R)-2-((2-氨基-5-(((S)-1-苯乙基)硫基)噻唑并[4,5-d]嘧啶-7-基)氨基)-4-甲基戊-1-醇

(R)-2-((2-Amino-5-(((S)-1-phenylethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)-4-methylpentan-1-ol | (2R)-2-[[2-amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-1-pentanol | AZD 8797 | KAND567 | KAN-0440567

AZD8797

A649378-5mg

5mg

≥98%

-20°C储存,充氩

超低温冰袋运输

AZD8797 (KAND567) 是一种可口服且具有选择性和有效性的人 CX3CR1 变构拮抗剂，对 CX3CR1 和 CXCR2 具有抑制作用，对SARS-CoV-2诱导的神经元损伤有潜在的保护作用，可防止癫痫发作后偏头痛模型大鼠痛觉过敏和小胶质细胞活化的恶化。 AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2, and potentially protects against SARS-CoV-2-induced neuronal damage, preventing worsening of nociceptive sensitization and microglial activation in a migraine model of rats following seizures.

AZD8797 (KAND567) 是人 CX3CR1 受体的异构非竞争性口服活性拮抗剂；可拮抗 CX3CR1 和 CXCR2，其 K i s 分别为 3.9 和 2800 nM。

911715-90-7

C19H25N5OS2

403.56 g/mol

11965767

C[C@@H](C1=CC=CC=C1)SC2=NC3=C(C(=N2)N[C@H](CC(C)C)CO)SC(=N3)N

(2R)-2-[[2-amino-5-[(1S)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol

1S/C19H25N5OS2/c1-11(2)9-14(10-25)21-16-15-17(22-18(20)27-15)24-19(23-16)26-12(3)13-7-5-4-6-8-13/h4-8,11-12,14,25H,9-10H2,1-3H3,(H3,20,21,22,23,24)/t12-,14+/m0/s1

ZMQSLMZOWVGBSM-GXTWGEPZSA-N

CC(C)CC(CO)NC1=NC(=NC2=C1SC(=N2)N)SC(C)C3=CC=CC=C3

11965767

DMSO : ≥ 150 mg/mL (371.69 mM)

3

8

8

403.15 Da

403.15 Da

150.000 Ų

27

0

452

0

1

4.8